Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
NEW YORK, Aug. 07, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-05011) against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities that acquired Ocular securities between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”). If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke ([email protected]) or Jonathan Dilger ([email protected]); (866) 540-5505.
The Complaint alleges that, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing issues concerning the manufacture of its lead product, Dextenza, including that more than half the lots the Company produced contained bad product; (2) the foregoing issues could jeopardize Dextenza’s prospects of approval by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Ocular securities during the Class Period, we encourage you to contact us with any questions prior to the September 5, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England, and Milan, Italy. SFMS has recovered hundreds of millions of dollars on behalf of investors. For more information visit us at http://www.sfmslaw.com.
Contacts: Bruce Parke Jonathan Dilger Shepherd Finkelman Miller & Shah, LLP www.sfmslaw.com Telephone: (866) 540-5504 Email: [email protected] [email protected]
